196 related articles for article (PubMed ID: 11449871)
21. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Br J Haematol; 2009 Jan; 144(1):78-85. PubMed ID: 19016731
[TBL] [Abstract][Full Text] [Related]
23. The evolving role of alemtuzumab in management of patients with CLL.
Faderl S; Coutré S; Byrd JC; Dearden C; Denes A; Dyer MJ; Gregory SA; Gribben JG; Hillmen P; Keating M; Rosen S; Venugopal P; Rai K
Leukemia; 2005 Dec; 19(12):2147-52. PubMed ID: 16239912
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia.
Laurenti L; Tarnani M; Efremov DG; Chiusolo P; De Padua L; Sica S; Leone G
Leukemia; 2007 Aug; 21(8):1819-21; author reply 1821. PubMed ID: 17443222
[No Abstract] [Full Text] [Related]
25. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Leukemia; 2006 Dec; 20(12):2204-7. PubMed ID: 17051245
[No Abstract] [Full Text] [Related]
26. Alemtuzumab in chronic lymphocytic leukemia.
James DF; Kipps TJ
Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
[TBL] [Abstract][Full Text] [Related]
27. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
[TBL] [Abstract][Full Text] [Related]
28. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
Lee D
Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612
[No Abstract] [Full Text] [Related]
29. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Robak T
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
[TBL] [Abstract][Full Text] [Related]
30. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia?
Smith JA
Cancer Pract; 2001; 9(4):211-3. PubMed ID: 11879313
[No Abstract] [Full Text] [Related]
31. Update on monoclonal antibody therapy in chronic lymphocytic leukemia.
Zent CS; Kay NE
Clin Adv Hematol Oncol; 2004 Feb; 2(2):107-13. PubMed ID: 16163170
[TBL] [Abstract][Full Text] [Related]
32. [Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics].
Doubek M; Jungová A; Brejcha M; Panovská A; Brychtová Y; Pospísil Z; Mayer J;
Vnitr Lek; 2009 Jun; 55(6):549-54. PubMed ID: 19662885
[TBL] [Abstract][Full Text] [Related]
33. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.
Pettitt AR; Matutes E; Oscier D
Leukemia; 2006 Aug; 20(8):1441-5. PubMed ID: 16738694
[No Abstract] [Full Text] [Related]
34. Alemtuzumab: what is the secret to safe therapy?
Elter T; Hallek M; Montillo M
Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
[TBL] [Abstract][Full Text] [Related]
35. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl M; Falkner A; Hopfinger G; Brugger S; Zabernigg A; Bauer F; Haslbauer F; Demirtas D; Grossschmidt P; Tatzreiter G; Gastl G; Greil R;
Cancer; 2006 Nov; 107(10):2408-16. PubMed ID: 17054106
[TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52.
Keating M; Hallek M
Med Oncol; 2002; 19 Suppl():S1-2. PubMed ID: 12180486
[No Abstract] [Full Text] [Related]
37. [A new therapeutic alternative in chronic B-lymphocytic leukemia].
Portal E
Rev Infirm; 2002 Dec; (86):38-40. PubMed ID: 12630232
[No Abstract] [Full Text] [Related]
38. Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?
Oberoi SS; Abou Jawde RM
J Clin Oncol; 2008 Dec; 26(35):5827-8; author reply 5828-9. PubMed ID: 19001335
[No Abstract] [Full Text] [Related]
39. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
O'Brien SM; Keating MJ; Mocarski ES
Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
[TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention.
Worth LJ; Thursky KA
Leuk Lymphoma; 2006 Dec; 47(12):2435-6. PubMed ID: 17169785
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]